Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.

ABSTRACT:

Objective

To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.

Design

Double-blind, placebo-controlled clinical trial.

Setting

Academic medical centers.

Participants

Subjects with mild to moderate Alzheimer disease.

Intervention

Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo.

Main outcome measures

Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily L

SUBMITTER: Galasko DR 

PROVIDER: S-EPMC3661272 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature